Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Blood (2022) 140 (Supplement 1): 7219–7221.

https://doi.org/10.1182/blood-2022-165913

Published: 2022

Journal Articles

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Blood (2021) 138 (Supplement 1): 4379.

https://doi.org/10.1182/blood-2021-148678

Published: 2021

Journal Articles

Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140713

Published: 2020

Journal Articles

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

Mauricette Michallet, MD PhD, Mohamad Sobh, PharmD, Romain Buono, Solene Poirey, Isabela Pascu, Emmanuelle Nicolas-Virelizier, MD, Souad Assaad, MD, Amine Belhabri, Laure Lebras, MD, Yann Guillermin, MD, Philippe Rey, MD, Lila Gilis, MD, Franck E Nicolini, MD PhD, Stephane Morisset, BioStat, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, MD PhD, Beatrice Fervers, Anne-Sophie Michallet, MD PhD

Blood (2019) 134 (Supplement_1): 5817.

https://doi.org/10.1182/blood-2019-130597

Published: 2019

Journal Articles

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

Blood (2018) 132 (Supplement 1): 1444.

https://doi.org/10.1182/blood-2018-99-112825

Published: 2018

Journal Articles

How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Eve Poret, Chrystelle Vidal, Yohan Desbrosses, Fanny Angelot Delettre, Maider Pagadoy, Aurore Pugin, Louis Benazet, Franck Leroux, Elise Robert, Delphine Binda, Sabeha Biichle, Anne Roggy, PhDSTUDENT, Laure Philippe, MDcal student, Berengere Gruson, Anne-Claire Gac, Michel Maigre, Denis Caillot, Remy Gressin, MD, Pascal Turlure, MD, Anne-Sophie Michallet, MD, Lila Gilis, Veronique Dorvaux, Yazid Arkam, Caroline Bonmati, MD, Pierre Péterlin, Pierre-Simon Rohrlich, MD PhD, Thorsten Braun, MD PhD, jean-Valere Malfuson, Didier Bouscary, MDPhD, Eric Pujade-Lauraine, Felipe Suarez, MD PhD, Carole Soussain, MD, Etienne Lengliné, MD, Mathieu Puyade, MD, Tony Marchand, MD, Denis Guyotat, Bruno Lioure, MD, Christian Recher, MD, Damien Roos-Weil, Fabrice Jardin, Jean-Pierre Marolleau, Bernard Drenou, MD, Bernard Bonnotte, MD PhD, Sophie Dalac, Philippe Saas, PhD, Francine Garnache Ottou, PhD, Eric Deconinck

Blood (2015) 126 (23): 456.

https://doi.org/10.1182/blood.V126.23.456.456

Published: 2015

Journal Articles

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3892.

https://doi.org/10.1182/blood.V124.21.3892.3892

Published: 2014

Journal Articles

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Mohamed Elhamri, PhD, Jeremy Monfray, CRA, Helene Labussiere-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Adriana Plesa, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 3691.

https://doi.org/10.1182/blood.V124.21.3691.3691

Published: 2014

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Jeremy Monfray, CRA, Hélène Labussière-Wallet, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed Elhamri, PhD, Lila Gilis, MD, Laure L Lebras, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valerie Dubois, Franck E. Nicolini, MD PhD, Xavier Thomas, MD PhD

Blood (2014) 124 (21): 2542.

https://doi.org/10.1182/blood.V124.21.2542.2542

Published: 2014

Journal Articles

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M, Helene Labussiere, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Madeleine Etienne, CRA, Oriane Le Borgne, CRA, Isabelle Tigaud, MD, Sandrine Hayette, PhD, Sophie Ducastelle, MD, Xavier Thomas, MD

Blood (2013) 122 (21): 2721.

https://doi.org/10.1182/blood.V122.21.2721.2721

Published: 2013

Journal Articles

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Marie Y. Detrait, MD, Helene Labussiere, MD, Sandrine Hayette, PhD, Isabelle Tigaud, MD, Mohamed El Hamri, PhD, Lila Gilis, MD, Fiorenza Barraco, MD, Sophie Ducastelle, MD, Valentina Bozzoli, MD, Franck E. Nicolini, MD, PhD, Xavier Thomas, MD

Blood (2013) 122 (21): 2162.

https://doi.org/10.1182/blood.V122.21.2162.2162

Published: 2013

Journal Articles

Oral Mucositis After Allogeneic Hematopoietic Stem Cell Transplantation: Important Impact Of The Presence Of Aciclovir-Resistant Herpes Simplex Virus (HSV-1) On Its Occurrence

Emilie Frobert, MD, Mohamad Sobh, Pharm.M., Florence Morfin, MD, Helene Labussiere, MD, Sophie Ducastelle, MD, Lila Gilis, MD, Fiorenza Barraco, MD, Vanessa Escuret, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Bruno Lina, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 1048.

https://doi.org/10.1182/blood.V122.21.1048.1048

Published: 2013

Journal Articles

Significant Impact Of Iron Chelation After Allogeneic Hematopoetic Stem Cell Transplantation On Disease Recurrence: Potential Anti-Leukemic Activity

Mauricette Michallet, MD, PhD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Lila Gilis, MD, Richard Cohen, Tech., Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Colette Chapuis-Cellier, MD

Blood (2013) 122 (21): 180.

https://doi.org/10.1182/blood.V122.21.180.180

Published: 2013

Journal Articles

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

Florence Beckerich, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Adriana Plesa, MD, Valerie Dubois, MD, Isabelle Mollet, Helene Labussiere, MD, Lila Gilis, MD, Sophie Ducastelle, MD, Oriane Le Borgne, CRA, Jeremy Monfray, CRA, Fiorenza Barraco, MD, Isabelle Tigaud, MD, Xavier Thomas, MD, Franck E. Nicolini, MD, PhD, Mauricette Michallet, MD, PhD

Blood (2013) 122 (21): 4639.

https://doi.org/10.1182/blood.V122.21.4639.4639

Published: 2013

Journal Articles

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Lila Gilis, MD, Madeleine Etienne, CRA, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Helene Labussiere, MD, Luc Gerland, MD, Damien Waz, MStud, Mohamad Sobh, Pharm., M, Stephane Morisset, Stat., Mauricette Michallet

Blood (2010) 116 (21): 3407.

https://doi.org/10.1182/blood.V116.21.3407.3407

Published: 2010

NARROW

Low Non Relapse Mortality and Good Hematological Response after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective Société Francaise De Greffe De Moelle-Thérapie Cellulaire Observational Study

Therapy-Related Acute Myeloid Leukemia (t-AML) and the Advantage of Intensive Chemotherapy: Real-Life Analysis from Two Regional French Centers

Acceptable Toxicity and Good Hematological and Renal Responses after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma Patients with Renal Insufficiency at Transplant: A Prospective SFGM-TC Observational Study

Personalised Follow-up Program after Acute Phase of Treatment in Oncology/Hematology Patients Towards Early Intervention, Better Care and Quality of Life Improvement: Results from Pasca Pilot Study

The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial

How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network

Flamsa Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation for High Risk Acute Myeloid Leukemia Patients

Therapeutic Management of Acute Myeloid Leukemia Patients after Stratification on Age, Prognosis and Allogeneic Hematopoietic Stem Cell Transplantation Eligibility

Allogeneic Hematopoietic Stem Cell Transplantation for Therapy-Related Acute Myeloid Leukemia

Impact Of Major Molecular Response On Overall Survival and Its Time Of Achievement On Complete Molecular Response Incidence In Chronic Myeloid Leukemia Patients Treated By Tyrosine Kinase Inhibitors In First Chronic Phase

Sequential Chemotherapy Followed By Reduced Intensity Conditioning and Allogeneic Hematopoietic Transplantation For High Risk Acute Myeloid Leukemia Patients In First Complete Remission: A Prospective Pilot Study

Oral Mucositis After Allogeneic Hematopoietic Stem Cell Transplantation: Important Impact Of The Presence Of Aciclovir-Resistant Herpes Simplex Virus (HSV-1) On Its Occurrence

Significant Impact Of Iron Chelation After Allogeneic Hematopoetic Stem Cell Transplantation On Disease Recurrence: Potential Anti-Leukemic Activity

A Significant Early Detection Of Poor Outcome In Acute Myeloid Leukemia Patients Having a Minimal Residual Disease Using Multiparameter Flow Cytomerty Combined To Mixed Chimerism At Three Months After Allogeneic Hematopoietic Stem Cell Transplantation

The Achievement of Early Major Molecular Response In Early Chronic Phase Chronic Myeloid Leukemia on Imatinib 400 Mg/Day Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only